BIOMAT Database Logo BIOMAT Database Logo

Gas chromatographic analysis of metabolites of the cell differentiating agent hexamethylene bisacetamide. 1987

M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery

UI MeSH Term Description Entries
D002849 Chromatography, Gas Fractionation of a vaporized sample as a consequence of partition between a mobile gaseous phase and a stationary phase held in a column. Two types are gas-solid chromatography, where the fixed phase is a solid, and gas-liquid, in which the stationary phase is a nonvolatile liquid supported on an inert solid matrix. Chromatography, Gas-Liquid,Gas Chromatography,Chromatographies, Gas,Chromatographies, Gas-Liquid,Chromatography, Gas Liquid,Gas Chromatographies,Gas-Liquid Chromatographies,Gas-Liquid Chromatography
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000081 Acetamides Derivatives of acetamide that are used as solvents, as mild irritants, and in organic synthesis.
D001711 Biotransformation The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.

Related Publications

M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Simultaneous measurement of the cell-differentiating agent hexamethylene bisacetamide and its metabolites by gas chromatography.
February 1994, Journal of chromatography,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Identification of metabolites of the cell-differentiating agent hexamethylene bisacetamide in humans.
October 1986, Cancer research,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
An active, aldehydic metabolite of the cell-differentiating agent hexamethylene bisacetamide.
January 1989, Drug metabolism and disposition: the biological fate of chemicals,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Cancer Differentiating Agent Hexamethylene Bisacetamide Inhibits BET Bromodomain Proteins.
April 2016, Cancer research,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Differentiating agent, hexamethylene bisacetamide, inhibits neointimal formation after vascular injury.
January 1997, Coronary artery disease,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
December 1990, Journal of the National Cancer Institute,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Hexamethylene bisacetamide: a polar-planar compound entering clinical trials as a differentiating agent.
August 1986, Cancer treatment reports,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Involvement of monoamine oxidase and diamine oxidase in the metabolism of the cell differentiating agent hexamethylene bisacetamide (HMBA).
January 1988, Life sciences,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
The effect of the monoamine oxidase inhibitor isocarboxazid on the canine metabolism of the cell-differentiating agent hexamethylene bisacetamide.
January 1991, Cancer chemotherapy and pharmacology,
M J Egorin, and E G Zuhowski, and M S Nayar, and P S Callery
Determination of hexamethylene bisacetamide by capillary gas chromatography.
March 1987, Journal of chromatography,
Copied contents to your clipboard!